Search the Newsreel

Vardhman Special Steels Share Price Target 2027 to 2030: Analyst

Tvardi: Q2 Earnings Snapshot

Mirae Asset Global Investments Co. Ltd. Purchases 56,424 Shares of Novartis AG $NVS

Mirae Asset Global Investments Co. Ltd. significantly increased its stake in Novartis AG (NVS) by 40.4% in the second quarter, acquiring an additional 56,424 shares, bringing its total holdings to 195,986 shares valued at approximately $30.7 million. Other institutional investors also expanded their positions, …

VBL Share Price Today - Varun Beverages Stock Analysis

Varroc Engineer Consolidated June 2026 Net Sales at Rs 2,634.24 crore, up 29.92% Y-o-Y

Solvar (ASX:SVR) Dividend Focus: Assessing Franking Benefits, Yield and Future Income Factors

Pharvaris President Lu Peng Reports Two RSU Tax Withholding Share Dispositions

Pharvaris N.V. President Lu Peng reported two share dispositions on August 11 and 12, 2026, totaling 226 shares. These transactions were related to shares withheld by the company to cover tax obligations arising from RSU vesting. Following these dispositions, Lu Peng's direct beneficial ownership …

Pharvaris (NASDAQ:PHVS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

REG - Chenavari Toro IncFd - Scrip Dividend Election Price

Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent

(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade …

Novartis Wins UK Court Challenge to Entresto Patent

Novartis has successfully defended its patent for the blockbuster heart drug Entresto in a UK court challenge. The article, published by MT Newswires, indicates this as a significant win for the pharmaceutical giant. Further details require a membership to the financial news platform.

Pharvaris (NASDAQ:PHVS) Given New $75.00 Price Target at Citizens Jmp

Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent

Novartis has successfully defended its patent for the heart drug Entresto in a UK court against Accord Healthcare, a subsidiary of Intas Pharmaceuticals, which intended to launch a generic version. The High Court rejected Accord's claim that Novartis's patent was invalid, affirming the patent's …

HC Wainwright Has Pessimistic View of Savara FY2029 Earnings

HC Wainwright has revised its FY2029 EPS forecast for Savara Inc. (NASDAQ:SVRA) down to $0.09 from $0.11, while projecting FY2030 EPS at $0.37. This revision is still notably above the current full-year consensus estimate of a $0.57 loss per share. Savara recently reported a …

Novartis AG $NVS Shares Purchased by Mission Wealth Management LP

Mission Wealth Management LP significantly increased its stake in Novartis AG (NYSE:NVS) during the second quarter, purchasing an additional 9,086 shares to bring its total holdings to 19,690 shares valued at approximately $3.09 million. Other institutional investors also expanded their positions, though hedge funds …

SOA Wealth Advisors LLC. Buys 14,416 Shares of Novartis AG $NVS

SOA Wealth Advisors LLC. significantly increased its stake in Novartis AG (NYSE:NVS) by 4,316.2% in the second quarter, acquiring 14,416 additional shares to reach a total of 14,750 shares valued at $2.31 million. Other institutional investors also adjusted their positions in Novartis, with institutions …

BOE Varitronix Sets August Board Meeting to Approve Interim Results and Consider Dividend

Pharvaris (NASDAQ:PHVS) Reaches New 12-Month High - What's Next?

Pharvaris (NASDAQ:PHVS) recently hit a new 52-week high of $36.65, with a current market capitalization of $2.38 billion, despite missing its latest quarterly earnings estimate. Analyst sentiment is generally positive with a "Moderate Buy" consensus and an average price target of $50.08, though some …

Citizens raises Pharvaris stock price target to $75 on trial progress

Citizens has increased its price target for Pharvaris B.V. to $75.00 from $74.00, maintaining a Market Outperform rating, due to ongoing trial progress. The company's stock has surged 70% in the past year, and key Phase 3 CHAPTER-3 data is expected this quarter. Pharvaris …

Dimensional Fund Advisors LP Has $4.36 Million Stock Holdings in Varonis Systems, Inc. $VRNS

Dimensional Fund Advisors LP significantly increased its stake in Varonis Systems, Inc. (NASDAQ:VRNS) by 556% in the first quarter, now holding 203,037 shares valued at approximately $4.36 million. This move is part of broader institutional interest, with hedge funds owning 95.65% of the company. …

Quantinno Capital Management LP Has $1.65 Million Stock Holdings in Varonis Systems, Inc. $VRNS

Quantinno Capital Management LP significantly increased its stake in Varonis Systems, Inc. by 59% in Q1, bringing its total holdings to $1.65 million. Varonis Systems reported strong Q2 revenue and EPS that exceeded analyst expectations, though the company continues to operate with negative net …

AlTi Global (ALTI) Stock Drifts As AUM Climbs Yet Losses Linger

AlTi Global's stock saw a slight increase after its Q2 2026 earnings report, with assets under management (AUM) rising to US$49.7 billion due to net inflows. Despite this growth in AUM, the company continues to report losses, with a basic loss per share of …

How Record Q2 Results and the Vipal Deal At Savaria (TSX:SIS) Have Changed Its Investment Story

Benchmark raises Harvard Bioscience stock price target on revenue beat

Benchmark has increased its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00, maintaining a Speculative Buy rating after the company surpassed second-quarter revenue guidance. The company reported $22.7 million in revenue, exceeding both management's and consensus estimates, and subsequently raised its full-year …

Vardhman Special Steels vs Sunflag Iron and Steel: Share Price, PE and ROE Compared

How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf

Savara Inc. reported a wider Q2 2026 net loss of US$40.23 million and filed a US$108.30 million shelf registration for common shares, primarily for an ESOP-related offering. Despite the financial losses and potential dilution, the company's investment narrative remains tied to upcoming regulatory decisions …

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's What Happened

Pharvaris (NASDAQ:PHVS) experienced unusually high trading volume, with 487,339 shares traded, marking a 60% increase from the previous session. The stock closed at $34.48, and analysts maintain a "Moderate Buy" rating with an average price target of $50.08 despite the company missing quarterly EPS …

Pharvaris (NASDAQ:PHVS) Releases Earnings Results, Misses Expectations By $0.05 EPS

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics reported its second-quarter 2026 financial results, highlighting $73.9 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which is expected to fund operations into late 2027. The company is actively assessing unblinded Phase 3 HERO and OLE data …

(PHVS) as a Liquidity Pulse for Institutional Tactics

This article provides a detailed AI-driven analysis of Pharvaris N.v. (NASDAQ: PHVS), highlighting a strong near-term sentiment moving towards a long-term positive bias. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and specific entry, target, and stop-loss …

Earnings Flash (PHVS) Pharvaris Posts Q2 Loss 0.70 Euro a Share

Pharvaris (PHVS) boosts cash to €318M as deucrictibant nears key data and FDA date

Harvard Ave Acquisition Ord Shs Class A (HAVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Pharvaris Reports Q2 2026 Results and Updates on Deucrictibant Development, Regulatory Progress and Financial Position

Pharvaris reported its Q2 2026 financial results, with cash and cash equivalents of €318 million, providing a financial runway into 2028. The company is advancing deucrictibant for bradykinin-mediated angioedema, with topline data from the pivotal Phase 3 CHAPTER-3 study expected in Q3 2026, and …

The Manufacturers Life Insurance Company Sells 833,712 Shares of Varonis Systems, Inc. $VRNS

The Manufacturers Life Insurance Company significantly reduced its stake in Varonis Systems, Inc. (NASDAQ:VRNS) by selling 833,712 shares, decreasing its holdings by 93.9% to 54,001 shares. Despite this large sale, institutional investors still hold 95.65% of the company's stock. Varonis reported strong quarterly revenue …

Pharvaris N.V. $PHVS Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company significantly reduced its stake in Pharvaris N.V. by 44.7% in Q1 2026, selling 35,695 shares. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $50.08, while company insiders have recently sold a substantial number …